European Regulator Accepts Mitsubishi Tanabe’s Edaravone Filing for ALS

May 29, 2018
Mitsubishi Tanabe Pharma said on May 28 that the European Medicines Agency (EMA) has accepted the company’s filing for its free-radical scavenger edaravone for the suppression of functional disorder in amyotrophic lateral sclerosis (ALS). Edaravone bagged Japan approved in April...read more